|
10 Jan 2022 |
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
|
|
10 Jan 2022 |
Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection
|
|
10 Jan 2022 |
Vaxiion Therapeutics Announces Clearance of IND Application for the Intralesional Administration of VAX014 to Subjects with Treatment Refractory Solid Tumors
|
|
10 Jan 2022 |
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
|
|
10 Jan 2022 |
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
|
|
10 Jan 2022 |
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
|
|
10 Jan 2022 |
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
|
|
10 Jan 2022 |
Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
|
|
10 Jan 2022 |
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
|
|
10 Jan 2022 |
European Commission approves Lumykras® (sotorasib) for patients with KRAS G12C-mutated advanced non-small cell lung cancer
|
|
08 Jan 2022 |
Absci Announces Research Collaboration with Merck
|
|
08 Jan 2022 |
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States
|
|
08 Jan 2022 |
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
|
|
08 Jan 2022 |
AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
|
|
07 Jan 2022 |
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
|
|
07 Jan 2022 |
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
|
|
07 Jan 2022 |
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
|
|
07 Jan 2022 |
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
|
|
07 Jan 2022 |
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
|
|
07 Jan 2022 |
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
|
